Nuclear receptors and their coregulators in kidney

Kidney International

Volumn 68, Issue 6, 2005, Pages 2444-2461

  Ruan, Xiong Z ^a   Varghese, Zac ^a   Powis, Stephen H ^a   Moorhead, John F ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Kidney disease; Nuclear receptor; Nuclear receptor coregulator

Indexed keywords

CELL NUCLEUS RECEPTOR; PROTEIN P160; PROTEIN P300; REGULATOR PROTEIN; RETINOIC ACID; THYROID HORMONE RECEPTOR;

ACETYLATION; APOPTOSIS; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL METABOLISM; CELL PROLIFERATION; DISEASE COURSE; EMBRYO DEVELOPMENT; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; LIGAND BINDING; LIPID METABOLISM; METHYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 32844460630     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00721.x     Document Type: Article

References (152)

1. FRANCIS GA, FAYARD E, PICARD F, et al: Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261-311, 2003
2. MANGELSDORF DJ, THUMMEL C, BEATO M, et al: The nuclear receptor superfamily: The second decade. Cell 83:835-839, 1995
3. ROSENFELD MG, GLASS CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865-36868, 2001
4. DANIELIAN PS, WHITE R, LEES JA, et al: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033, 1992
5. DURAND B, SAUNDERS M, GAUDON C, et al: Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J 13:5370-5382, 1994
6. GLASS CK, ROSE DW, ROSENFELD MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232, 1997
7. WESTIN S, KUROKAWA R, NOLTE RT, et al: Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199-202, 1998
8. BOURGUET W, RUFF M, BONNIER D, et al: Purification, functional characterization, and crystallization of the ligand binding domain of the retinoid X receptor. Protein Expr Purif 6:604-608, 1995
9. PERISSI V, STASZEWSKI LM, MCINERNEY EM, et al: Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13:3198-3208, 1999
10. WAGNER BL, VALLEDOR AF, SHAO G, et al: Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 23:5780-5789, 2003
11. AUPHAN N, DIDONATO JA, ROSETTE C, et al: Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290, 1995
12. JONAT C, RAHMSDORF HJ, PARK KK, et al: Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189-1204, 1990
13. SCHULE R, RANGARAJAN P, YANG N, et al: Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci USA 88:6092-6096, 1991
14. GUSTAFSSON JA: What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci 24:479-485, 2003.
15. GIGUERE V, HOLLENBERG SM, ROSENFELD MG, et al: Functional domains of the human glucocorticoid receptor. Cell 46:645-652, 1986
16. HERMANSON O, GLASS CK, ROSENFELD MG: Nuclear receptor coregulators: Multiple modes of modification. Trends Endocrinol Metab 13:55-60, 2002
17. MORAS D, GRONEMEYER H: The nuclear receptor ligand-binding domain: Structure and function. Curr Opin Cell Biol 10:384-391, 1998
18. CHEN D, MA H, HONG H, et al: Regulation of transcription by a protein methyltransferase. Science 284:2174-2177, 1999
19. KOH SS, CHEN D, LEE YH, et al: Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem 276:1089-1098, 2001
20. HEERY DM, KALKHOVEN E, HOARE S, et al: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736, 1997
21. XU J, QIU Y, DEMAYO FJ, et al: Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922-1925, 1998
22. ANZICK SL, KONONEN J, WALKER RL, et al: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968, 1997
23. KO L, CARDONA GR, CHIN WW: Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 97:6212-6217, 2000
24. YANG XJ, OGRYZKO VV, NISHIKAWA J, et al: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324, 1996
25. NAKAJIMA T, UCHIDA C, ANDERSON SF, et al: RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112, 1997
26. CHEN H, LIN RJ, SCHILTZ RL, et al: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580, 1997
27. SMITH CL, ONATE SA, TSAI MJ, et al: CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93:8884-8888, 1996
28. TORCHIA J, ROSE DW, INOSTROZA J, et al: The transcriptional coactivator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684, 1997
29. STROMBERG H, SVENSSON SP, HERMANSON O: Distribution of CREB-binding protein immunoreactivity in the adult rat brain. Brain Res 818:510-514, 1999
30. JAIN S, PULIKURI S, ZHU Y, et al: Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 153:349-354, 1998
31. PUIGSERVER P, WU Z, PARK CW, et al: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839, 1998
32. Xu J, LIAO L, NING G, et al: The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97:6379-6384, 2000
33. WANG Z, ROSE DW, HERMANSON O, et al: Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA 97:13549-13554, 2000
34. KORZUS E, TORCHIA J, ROSE DW, et al: Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279:703-707, 1998
35. LAVINSKY RM, JEPSEN K, HEINZEL T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920-2925, 1998
36. SHANG Y, HU X, DIRENZO J, et al: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852, 2000
37. HORLEIN AJ, NAAR AM, HEINZEL T, et al: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404, 1995
38. KUROKAWA R, SODERSTROM M, HORLEIN A, et al: Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377:451-454, 1995
39. LEE JW, RYAN F, SWAFFIELD JC, et al: Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374:91-94, 1995
40. CHEN JD, EVANS RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457, 1995
41. JEPSEN K, HERMANSON O, ONAMI TM, et al: Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753-763, 2000
42. VEGETO E, ALLAN GF, SCHRADER WT, et al: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713, 1992
43. ZHANG X, JEYAKUMAR M, PETUKHOV S, et al: A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 12:513-524, 1998
44. LI H, LEO C, SCHROEN DJ, et al: Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. Mol Endocrinol 11:2025-2037, 1997
45. ZAMIR I, HARDING HP, ATKINS GB, et al: A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol 16:5458-5465, 1996
46. HU X, LAZAR MA: The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93-96, 1999
47. OGAWA S, LOZACH J, JEPSEN K, et al: A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc Natl Acad Sci USA 101:14461-14466, 2004
48. WU C: Chromatin remodeling and the control of gene expression. J Biol Chem 272:28171-28174, 1997
49. OWEN-HUGHES T, WORKMAN JL: Remodeling the chromatin structure of a nucleosome array by transcription factor-targeted transdisplacement of histones. EMBO J 15:4702-4712, 1996
50. EISEN JA, SWEDER KS, HANAWALT PC: Evolution of the SNF2 family of proteins: Subfamilies with distinct sequences and functions. Nucleic Acids Res 23:2715-2723, 1995
51. DINGWALL AK, BEEK SJ, MCCALLUM CM, et al: The Drosophila snr1 and brm proteins are related to yeast SWI/SNF proteins and are components of a large protein complex. Mol Biol Cell 6:777-791, 1995
52. KHAVARI PA, PETERSON CL, TAMKUN JW, et al: BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature 366:170-174, 1993
53. ICHINOSE H, GARNIER JM, CHAMBON P, et al: Ligand-dependent interaction between the estrogen receptor and the human homologues of SWI2/SNF2. Gene 188:95-100, 1997
54. MUCHARDT C, YANIV M: A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J 12:4279-4290, 1993
55. CHIBA H, MURAMATSU M, NOMOTO A, et al: Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucleic Acids Res 22:1815-1820, 1994
56. TURNER BM: Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol Life Sci 54:21-31, 1998
57. PAZIN MJ, KADONAGA JT: SWI2/SNF2 and related proteins: ATP-driven motors that disrupt protein-DNA interactions? Cell 88:737-740, 1997
58. BANNISTER AJ, KOUZARIDES T: The CBP co-activator is a histone acetyltransferase. Nature 384:641-643, 1996
59. OGRYZKO W, SCHILTZ RL, RUSSANOVA V, et al: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959, 1996
60. SPENCER TE, JENSTER G, BURCIN MM, et al: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194-198, 1997
61. KUROKAWA R, KALAFUS D, OGLIASTRO MH, et al: Differential use of CREB binding protein-coactivator complexes. Science 279:700-703, 1998
62. ZHU Y, QI C, CAO WQ, et al: Cloning and characterization of PIMT, a protein with a methyltransferase domain, which interacts with and enhances nuclear receptor coactivator PRIP function. Proc Natl Acad Sci USA 98:10380-10385, 2001
63. NAAR AM, BEAURANG PA, ZHOU S, et al: Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 398:828-832, 1999
64. ITO M, YUAN CX, MALIK S, et al: Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 3:361-370, 1999
65. HEINZEL T, LAVINSKY RM, MULLEN TM, et al: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48, 1997
66. NAGY L, KAO HY, CHAKRAVARTI D, et al: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380, 1997
67. XU L, GLASS CK, ROSENFELD MG: Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 9:140-147, 1999
68. ZHANG Y, SUN ZW, IRATNI R, et al: SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol Cell 1:1021-1031, 1998
69. LAHERTY CD, BILLIN AN, LAVINSKY RM, et al: SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell 2:33-42, 1998
70. GUENTHER MG, LANE WS, FISCHLE W, et al: A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 14:1048-1057, 2000
71. WEN YD, PERISSI V, STASZEWSKI LM, et al: The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci USA 97:7202-7207, 2000
72. MCNALLY JG, MULLER WG, WALKER D, et al: The glucocorticoid receptor: Rapid exchange with regulatory sites in living cells. Science 287:1262-1265, 2000
73. CHEN H, LIN RJ, XIE W, et al: Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686, 1999
74. STALLCUP MR: Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene 20:3014-3020, 2001
75. HOYT MA: Eliminating all obstacles: Regulated proteolysis in the eukaryotic cell cycle. Cell 91:149-151, 1997
76. LEE JW, CHOI HS, GYURIS J, et al: Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol 9:243-254, 1995
77. ZHANG J, GUENTHER MG, CARTHEW RW, et al: Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev 12:1775-1780, 1998
78. SUEN CS, BERRODIN TJ, MASTROENI R, et al: A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 273:27645-27653, 1998
79. CHRIVIA JC, KWOK RP, LAMB N, et al: Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859, 1993
80. AIT-SI-ALI S, RAMIREZ S, BARRE FX, et al: Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396:184-186, 1998
81. XU L, LAVINSKY RM, DASEN JS, et al: Signal-specific co-activator domain requirements for Pit-1 activation. Nature 395:301-306, 1998
82. HU E, KIM JB, SARRAF P, et al: Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274:2100-2103, 1996
83. HONG SH, PRIVALSKY ML: The SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol 20:6612-6625, 2000
84. KIM HJ, YI JY, SUNG HS, et al: Activating signal cointegrator 1, a novel transcription coactivator of nuclear receptors, and its cytosolic localization under conditions of serum deprivation. Mol Cell Biol 19:6323-6332, 1999
85. BOUTELL JM, THOMAS P, NEAL JW, et al: Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 8:1647-1655, 1999
86. BAEUERLE PA, BALTIMORE D: NF-kappa B: Ten years after. Cell 87:13-20, 1996
87. GHOSH S, MAY MJ, KOPP EB: NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998
88. NA SY, LEE SK, HAN SJ, et al: Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J Biol Chem 273:10831-10834, 1998
89. GERRITSEN ME, WILLIAMS AJ, NEISH AS, et al: CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 94:2927-2932, 1997
90. KORZUS E, TORCHIA J, ROSE DW, et al: Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279:703-707, 1998
91. SHEPPARD KA, ROSE DW, HAQUE ZK, et al: Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19:6367-6378, 1999
92. YAN K, KUDO A, HIRANO H, et al: Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int 56:65-73, 1999
93. STAELS B, KOENIG W, HABIB A, et al: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393:790-793, 1998
94. INOUE I, SHINO K, NOJI S, et al: Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246:370-374, 1998
95. GUAN Y, BREYER MD: Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 60:14-30, 2001
96. HANG Li, XIONG Z. Ruan, STEPHEN H. Powis, et al: EPA and DHA reduce LPS induced inflammation responses in HK-2 cells: evidence for a PPAR-γ dependent mechanism. Kidney Int 67:867-74.2005
97. THURBERG BL, COLLINS T: The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 9:387-396, 1998
98. DELERIVE P, DE BOSSCHER K, BESNARD S, et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274:32048-32054, 1999
99. CERNUDA-MOROLLON E, RODRIGUEZ-PASCUAL F, KLATT P, et al: PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: Implications for mesangial cell activation by cytokines. J Am Soc Nephrol 13:2223-2231, 2002
100. KAMEI Y, XU L, HEINZEL T, et al: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414, 1996
101. ESCOUBET-LOZACH L, GLASS CK, WASSERMAN SI: The role of transcription factors in allergic inflammation. J Allergy Clin Immunol 110:553-564, 2002
102. ITO K, BARNES PJ, ADCOCK IM: Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20:6891-6903, 2000
103. RAINE AE, MARGREITER R, BRUNNER FP, et al: Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 7 (Suppl 2):7-35, 1992
104. MOORHEAD JF, CHAN MK, EL-NAHAS M, et al: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2:1309-1311, 1982
105. RUAN XZ, MOORHEAD JF, FERNANDO R, et al: Regulation of lipoprotein trafficking in the kidney: Role of inflammatory mediators and transcription factors. Biochem Soc Trans 32:88-91, 2004
106. MISHRA R, EMANCIPATOR SN, MILLER C, et al: Adipose differentiation- related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney. Am J Physiol Renal Physiol 286:F913-F921, 2004
107. ORY DS: Nuclear receptor signaling in the control of cholesterol homeostasis: Have the orphans found a home? Circ Res 95:660-670, 2004
108. ISSEMANN I, PRINCE RA, TUGWOOD JD, et al: The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 11:37-47, 1993
109. LAPSYS NM, KRIKETOS AD, LIM-FRASER M, et al: Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J Clin Endocrinol Metab 85:4293-4297, 2000
110. SCHOONJANS K, PEINADO-ONSURBE J, LEFEBVRE AM, et al: PPAR-alpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348, 1996
111. RUAN XZ, MOORHEAD JF, FERNANDO R, et al: PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14:593-600, 2003
112. WU J, ZHANG Y, WANG N, et al: Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol 287:F886-F895, 2004
113. JANOWSKI BA, WILLY PJ, DEVI TR, et al: An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383:728-731, 1996
114. ZHENG F, FORNONI A, ELLIOT SJ, et al: Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 282:F639-F648, 2002
115. GUAN Y: Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15:2801-2815, 2004
116. BAYLIS C, ATZPODIEN EA, FRESHOUR G, et al: Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854-860, 2003
117. DOGGRELL S: Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert Opin Investig Drugs 12:713-716, 2003
118. OPHERK C, TRONCHE F, KELLENDONK C, et al: Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol Endocrinol 18:1346-1353, 2004
119. BERNAL-MIZRACHI C, WENG S, FENG C, et al: Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9:1069-1075, 2003
120. JIANG S, TANAKA T, IWANARI H, et al: Expression and localization of P1 promoter-driven hepatocyte nuclear factor-4alpha (HNF4alpha) isoforms in human and rats. Nucl Recept 1:5, 2003
121. 3 receptors is decreased in both intestine and kidney of genetically diabetic db/db mice. Endocrinology 122:2436-2443, 1988
122. NICHOLAS SB, KAWANO Y, WAKINO S, et al: Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 37:722-727, 2001
123. GHOSH SS, GEHR TW, GHOSH S, et al: PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: Role of MAP kinase. Kidney Int 64:52-62, 2003
124. PANCHAPAKESAN U, POLLOCK CA, CHEN XM: The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol 287:F528-F534, 2004
125. MA LJ, MARCANTONI C, LINTON MF, et al: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59:1899-1910, 2001
126. 3 on human mesangial cells. Am J Kidney Dis 18:359-366, 1991
127. OSBORNE JE, HUTCHINSON PE: Vitamin D and systemic cancer: Is this relevant to malignant melanoma? Br J Dermatol 147:197-213, 2002
128. DUSSO AS, THADHANI R, SLATOPOLSKY E: Vitamin D receptor and analogs. Semin Nephrol 24:10-16, 2004
129. MEYER M, SONNTAG-BUCK V, KEAVENEY M, et al: Retinoid-dependent transcription: The RAR/RXR-TBP-EIA/EIA-LA connection. Biochem Soc Symp 62:97-109, 1996
130. LIEBLER S, UBERSCHAR B, KUBERT H, et al: The renal retinoid system: Time-dependent activation in experimental glomerulonephritis. Am J Physiol Renal Physiol 286:F458-F465, 2004
131. XU Q, KONTA T, KITAMURA M: Retinoic acid regulation of mesangial cell apoptosis. Exp Nephrol 10:171-175, 2002
132. SLAGSVOLD HH, OSTVOLD AC, FALLGREN AB, et al: Nuclear receptor and apoptosis initiator NGFI-B is a substrate for kinase ERK2. Biochem Biophys Res Commun 291:1146-1150, 2002
133. SEGELMARK M, BARRETT C, PENDERGRAFT W, et al: Expression of p300-truncated fragments results in the modulation of apoptosis in rat mesangial cells. Kidney Int 57:1873-1881, 2000
134. MATSUDA T, YAMAMOTO T, MURAGUCHI A, et al: Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 276:42908-42914, 2001
135. POTIER M, ELLIOT SJ, TACK I, et al: Expression and regulation of estrogen receptors in mesangial cells: Influence on matrix metalloproteinase-9. J Am Soc Nephrol 12:241-251, 2001
136. NEUGARTEN J, ACHARYA A, LEI J, et al: Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 279:F309-F318, 2000
137. NEUGARTEN J, SILBIGER SR: Effects of sex hormones on mesangial cells. Am J Kidney Dis 26:147-151, 1995
138. 2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal 4:877-884, 2002
139. ROUTH RE, JOHNSON JH, MCCARTHY KJ: Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 61:1365-1376, 2002
140. GUO B, KOYA D, ISONO M, et al: Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53:200-208, 2004
141. KANAMARU Y, NAKAO A, TANAKA Y, et al: Involvement of p300 in TGF-beta/Smad-pathway-mediated alpha2(I) collagen expression in mouse mesangial cells. Nephron Exp Nephrol 95:e36-e42, 2003
142. LAKKIS J, LU WX, WEIR MR: RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 5:408-417, 2003
143. CLAUSER E, GAILLARD I, WEI L, et al: Regulation of angiotensinogen gene. Am J Hypertens 2:403-410, 1989
144. DECHOW C, MORATH C, PETERS J, et al: Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis. Am J Physiol Renal Physiol 281:F909-F919, 2001
145. WU L, WANG R, DE CHAMPLAIN J, et al: Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17:749-756, 2004
146. ISHIZUKA T, ITO O, TAN L, et al: Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertens Res 26:929-936, 2003
147. HONECK H, GROSS V, ERDMANN B, et al: Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension 36:610-616, 2000
148. TAMURA K, CHEN YE, HORIUCHI M, et al: LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc Natl Acad Sci USA 97:8513-8518, 2000
149. MENDELSOHN C, LOHNES D, DECIMO D, et al: Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development 120:2749-2771, 1994
150. INDRIDASON OS, QUARLES LD: Oral versus intravenous calcitriol: Is the route of administration really important? Curr Opin Nephrol Hypertens 4:307-312, 1995
151. SELA-BROWN A, RUSSELL J, KOSZEWSKI NJ, et al: Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats. Mol Endocrinol 12:1193-1200, 1998
152. KLIEWER SA, MOORE JT, WADE L, et al: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82, 1998